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ABSTRACT
Objective: To reach consensus about themost relevant comorbidities to study in multiple sclerosis
(MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may
support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such
studies.
Methods: We held an international workshop to meet these objectives, informed by a systematic
review of the incidence and prevalence of comorbidity in MS, and an international survey regard-
ing research priorities for comorbidity.
Results: We recommend establishing age- and sex-specific incidence and prevalence estimates
for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating
the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic
lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other
imaging parameters, health care utilization, employment, and mortality, including age, sex,
race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing
study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical tri-
als of treating comorbidity in MS are needed.
Conclusion: Our recommendations will help address knowledge gaps regarding the incidence,
prevalence, and effect of comorbidity on outcomes in MS. Neurology® 2016;86:1–8
GLOSSARY
CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; ICD 5 International Classification of Diseases; MS 5
multiple sclerosis; NARCOMS 5 North American Research Committee on Multiple Sclerosis.
Substantial heterogeneity in multiple sclerosis (MS)–related outcomes exists, but this remains
incompletely understood. Comorbidity may account for some of the observed heterogeneity in
outcomes in MS, yet its effect has only recently received attention. Comorbidity is common in
the general population, and is associated with higher mortality and increased health care utili-
zation.1 Despite evidence that comorbidity is common2 and affects outcomes in MS,3 important
knowledge gaps remain.
An international group of investigators in MS, epidemiology, clinical trial design, and comor-
bidity met in Toronto, Canada, on March 27–28, 2015, under the auspices of the International
Advisory Committee on Clinical Trials in MS, sponsored by the European Committee on
Treatment and Research in Multiple Sclerosis and the US National Multiple Sclerosis Society.
The workshop goals were to reach consensus about the most relevant comorbidities to study in
MS with respect to incidence, prevalence, and impact on outcomes; prioritize outcomes for such
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studies; and review datasets that may support
these studies. Comorbidity was also discussed
in the context of clinical trials, as described
elsewhere.4 The current article summarizes
the evidence related to comorbidity in MS that
was collated and reviewed in preparation for the
workshop, describes the limitations of the ex-
isting literature regarding comorbidity and MS,
and reports recommendations for future
research regarding comorbidity in MS that re-
sulted from the workshop. Specifically, we
review core concepts related to the definition
of comorbidity, findings from an international
survey regarding research priorities in comor-
bidity research, the key findings from a system-
atic review of the incidence and prevalence of
comorbidity in MS, and a systematic review of
the effect of comorbidity on outcomes in MS,
health behaviors in MS, and issues related to
measurement and analysis of comorbidity in
MS, which guided our recommendations.
CORE CONCEPTS Comorbidity is conceptualized
differently depending on whether the perspective is
clinical, epidemiologic, or health policy–based.5
The core concept is that more than one distinct
condition exists in an individual.5 Traditionally,
comorbidity refers to the total burden of illness
other than the index disease of interest, and typi-
cally focuses on chronic conditions. This definition
excludes complications that are a direct result of the
index disease. While both comorbidity and compli-
cations may influence outcomes, their etiologies
and types of interventions may differ. Throughout
this article, we focus on comorbidity. For some
conditions, such as immune-mediated neurologic
disease, it may be difficult to determine whether 2
distinct conditions exist (that is, MS and another
condition) or not (that is, the other condition alone
or MS alone), but such diagnostic decisions are not
the focus of this article. We also recognize that for
some conditions, such as depression or anxiety, it
may be difficult to distinguish between comorbidity
and complication or symptom of disease. However,
we have chosen to consider these conditions as
comorbidities rather than symptoms of MS
because in some individuals they appear to occur
independent of MS, such as when onset is many
years before clinical onset of MS, multiple factors
may contribute to depression or anxiety in MS,
which may or may not be MS-related, such as
genetic factors or psychosocial stressors, and they
have specific diagnostic criteria, unlike symptoms
such as fatigue.
Classic definitions of comorbidity do not include
health behaviors. However, behaviors such as smok-
ing and alcohol intake affect the risks of, and out-
comes of, chronic diseases, including MS.6 In other
diseases, such as lung cancer, health behaviors such as
smoking have independent effects on outcomes.7
Therefore, we considered health behaviors as a type
of comorbidity rather than simple confounders when
making our recommendations.
Conditions may co-occur due to chance, or be
more likely to be diagnosed because of increased
health system contacts due to the presence of a
chronic condition.5 Of greater interest is the co-
occurrence of disease due to etiologic mechanisms
such as direct causation, associated risk factors, het-
erogeneity, and independence. In direct causation,
one condition leads directly to another condition, as
observed when idiopathic thrombocytopenic purpura
arises from the use of alemtuzumab to treat MS.8
Common genetic or environmental risk factors may
lead to increased comorbidity. Smoking may underlie
the increased prevalence of lung disease in MS as
persons with MS smoke more than the general pop-
ulation.6 In heterogeneity, independent factors such
as age may be associated with co-occurrence of dis-
ease. Finally, 2 conditions may coexist because they
are secondary to a third, undiagnosed disease (inde-
pendence). For example, asthma and peripheral
neuropathy might both be due to Churg-Strauss syn-
drome. Such mechanistic questions are relevant to
understanding comorbidity in MS, but were not the
focus of our deliberations.
Comorbidity is one of several patient characteris-
tics, including genetics, age, sex, race, ethnicity, and
socioeconomic status, which are relevant to the clini-
cal presentation and management of MS.9,10 Socio-
economic status appears to account for some of the
disparity in disability observed between African
Americans and Caucasian Americans with MS.9
These factors may modify the associations between
comorbidity and outcomes in MS. Age, for example,
is a critical determinant of the degree of disability
experienced by persons with MS,11 suggesting that
progressive MS represents an age-related neurodegen-
erative process. Comorbidities such as hypertension,
diabetes, and hyperlipidemia also increase in fre-
quency with age, and can be conceptualized to accel-
erate brain aging,12 potentially accelerating disability
progression in MS.
Research regarding comorbidity can be grouped
into the following areas: the incidence and prevalence
of comorbidity; the effect of comorbidity on the
affected individual, health system, and society; the
mechanisms underlying the frequency of comorbidity
and its effect; and evaluation of interventions to pre-
vent comorbidities or to reduce their impact. Most
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research regarding comorbidity and MS has focused
on the first 2 areas.
INTERNATIONAL SURVEY Preparatory to the
workshop, we surveyed experts regarding their views
of the most relevant comorbidities and health behav-
iors to evaluate with respect to incidence, prevalence,
and their effect on MS outcomes. Survey design and
results are detailed in appendices e-1 and e-2 on the
Neurology® Web site at Neurology.org. The top 3
comorbidities deemed to be in greatest need of
study with respect to their effect on outcomes were
psychiatric disorders, cancer, and autoimmune
disease; the top 3 health behaviors were substance
use, alcohol use, and diet. The most important
research gaps identified were comorbidity as a
prognostic factor for MS outcomes, followed by
estimates of the frequency of comorbidity. With
respect to health behaviors, the most important
research gaps identified were their roles as
prognostic factors for MS, followed by their effect
on pharmacotherapy.
Comorbidity, health behaviors, and MS. Incidence and
prevalence of comorbidity. Preparatory to the workshop,
we reviewed the world (English-language) literature
regarding the incidence and prevalence of comorbidity
in MS.2 Based on meta-analyses of population-based
studies, the comorbidities with the highest incidence
were hypertension (3.73%; 95% confidence interval
[CI] 3.43–4.06%), stroke (2.73%; 95% CI 2.51–
2.95%), and cancer (any cancer 4.3%; 95% CI
2.67–6.1); however, population-based studies were
lacking for many conditions. The most prevalent co-
morbidities were depression (23.7%; 95% CI 17.4–
30.0%), anxiety (21.9%; 95% CI 8.76–35.0%),
hypertension (18.6%; 95% CI 13.9–23.2%), hyper-
lipidemia (10.9%; 95% CI 5.6–16.1%), and chronic
lung disease (10.0%; 95% CI 0–20.9%). Several co-
morbidities occur more often in the MS population
than the general population, including depression, anx-
iety, bipolar disorder, alcohol abuse, stroke, ischemic
heart disease, inflammatory bowel disease, irritable syn-
drome, seizure disorders, and sleep disorders.2
Valid, reliable estimates of the incidence and prev-
alence of comorbidity in MS are needed to inform the
design of studies assessing the impact of comorbidity,
support pharmacovigilance efforts, and direct clinical
programs aimed at mitigating the impact of comor-
bidity. However, we identified gaps in knowledge
regarding the epidemiology of comorbidity in MS.
First, most studies were conducted in few geographic
regions, mainly western Europe and North America.
Given worldwide variation in the burden of many
chronic diseases,13 estimates are needed from other
regions. Second, estimates of the incidence and prev-
alence of comorbidity varied widely, likely due to
heterogeneity in study design, bias, and true differ-
ences between populations. Common limitations
included the failure to report diagnostic criteria or
validation of the approach used to identify the MS
population or the comorbidity, lack of information
regarding the time period when the study was con-
ducted, and lack of a population-based design. Thus,
homogeneous and more rigorous study designs are
needed to clarify the true variation in incidence and
prevalence of comorbidity across regions and socio-
demographic groups. Reporting of age, sex, and
ethnicity-specific estimates, and standardization of
findings to a common population, would also
improve comparability of study findings. Third,
many potentially relevant comorbidities were infre-
quently evaluated. Finally, although many studies
evaluated the incidence and prevalence of multiple
comorbidities, the relationship of these comorbidities
to one another was rarely considered.
Effects of comorbidity. With increasing age, the prev-
alence of comorbidity increases in MS, typically when
disability is also accumulating. Therefore, the effect of
comorbidity on MS is likely to be important as MS
progresses. Preparatory to the workshop, we also sys-
tematically reviewed the association of comorbidity
with outcomes commonly reported in clinical trials
(relapses, disability, functional status, cognition,
MRI outcomes, pain, and fatigue; for methods, see
appendix e-3). We chose the same comorbidities as
those considered in our systematic review of the inci-
dence and prevalence of comorbidity in MS.2
We identified 35 publications from 32 unique
studies (table e-1 and appendix e-3).3,10,14–46 Most
studies evaluated psychiatric comorbidities (17) or vas-
cular comorbidities, including diabetes, hypertension,
hyperlipidemia, ischemic heart disease, and peripheral
vascular disease (6). Overall, the findings suggest that
comorbidity is associated with adverse outcomes in
MS. Depression, anxiety, and sleep disorders are con-
sistently associated with the presence and severity of
fatigue. Depression is also associated with impaired
cognitive function, but not relapses or disability. The
presence of physical comorbidities is associated with
greater disability at the time of MS diagnosis10; the
effect increased with an increasing number of comor-
bidities.10 Vascular comorbidities are associated with
more rapid progression of ambulatory disability.31
Serum lipid measurements not necessarily meeting cri-
teria for dyslipidemia have been associated with new
hyperintense and contrast-enhancing lesions on
MRI,43 and with disability progression,39,43 but not
with relapses.38 None of the studies evaluated the effect
of treating comorbidities on outcome.
However, most potentially relevant comorbidities
have not been studied and we identified few
population-based studies.40 Most study populations
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were clinic-based. Secondary analyses of clinical trial
data included even more selected populations.
Definitions of comorbidities differed across studies,
and most studies did not consider the potential con-
founding effects of treatment of the comorbidities on
outcome. Many studies were cross-sectional, preclud-
ing causal inferences. Finally, it was often unclear if
outcomes were assessed blind to comorbidity status.
Future studies should be longitudinal, and need to
enroll representative populations, use validated meth-
ods to assess comorbidity status and outcome, and
assess potential confounding factors. Harmonization
of data collection would facilitate comparisons across
studies.
Prevalence and effect of health behaviors. Nearly 50%
of persons with MS report ever smoking before MS
symptom onset, and up to 39% actively smoke at
the time of MS symptom onset.10 The prevalence of
definite or probable alcohol abuse or dependence
ranges from 3.96% to 18.2%.47 Excessive weight
and obesity are highly prevalent in the MS popula-
tion, affecting nearly 50% of individuals.48 Although
some inconsistencies exist,49 smoking appears to be
associated with more rapid disability progression,
accumulation of hyperintense lesions on MRI, and
greater brain atrophy.50 In a cross-sectional study of
423 persons with MS, those who consumed alcohol
for 15 years or less after MS onset had lower disability
on the Expanded Disability Status Scale (EDSS) and
higher brain volume than those who did not consume
alcohol or who consumed it for more than 15 years.24
In a Belgian study of 1,372 persons with MS, mod-
erate alcohol consumption was associated with a
reduced risk of progression to an EDSS score of 6.0
(cane).19 In the North American Research Committee
on Multiple Sclerosis (NARCOMS) cohort, obesity
was associated with an increased likelihood of pre-
senting with a relapsing, rather than progressive,
course at onset among women, independent of
age.51 In a cohort of Australians, body mass index
was not associated with relapse risk,38 but was associ-
ated with greater disability.39 An important limitation
is that most of these studies considered the effect of
only one health behavior on outcome, and did not
consider the confounding effects of comorbidity.
Future observational studies would benefit from con-
sidering the effects of comorbidities and health
behaviors concurrently, and should attempt to disen-
tangle the direction of causation between comorbidity
and MS outcomes.
Another important unknown is whether there are
interactions among co-occurring comorbidities and
health behaviors leading to additive or synergistic
effects on outcomes.5 Metabolic syndrome, for exam-
ple, is diagnosed when any 3 of the following are
present: abdominal obesity, hypertension, elevated
fasting glucose, high serum triglycerides, and low
high-density lipoprotein level. Metabolic syndrome
increases the risk of cardiovascular mortality beyond
that of its individual components.52 Therefore, these
associations need to be better understood. It is also
unknown whether the timing of the development of a
comorbidity, its severity, or its treatments are relevant
to its effects.
DATA SOURCES In a series of presentations, we re-
viewed issues related to comorbidity measurement.
Potential sources of comorbidity data include self-
report, medical records, and administrative
databases. None of these data sources is the gold
standard in all circumstances. Briefly, the validity
and reliability of self-reported comorbidity in MS
varies by condition.53 Accuracy is high for chronic
conditions that are well-defined, require ongoing
care, or cause disability.53 Self-report is less accurate
for conditions where diagnostic criteria are less
precise, such as arthritis, and may vary in accuracy
by sociodemographic characteristics.
The medical record offers information about
comorbidity and MS, including disability status,
and treatments used. However, medical records re-
views may be costly and labor-intensive. When mul-
tiple health care providers are involved, it may be
difficult to access complete information. Therefore,
medical records reviews are often not feasible for
large, population-based studies. Depending on the
data sources used to construct a clinical database, they
may be subject to the aforementioned limitations of
self-report, medical records, or both.
Administrative data are obtained from enrolment
into public and commercial health insurance plans as
well as through the delivery of, and reimbursement
for, health care services.54 These data generally include
demographic characteristics including a personal iden-
tification number, date of birth, sex, and region of
residence, but race is often lacking. Most administra-
tive datasets capture hospital and physician encounters,
including the dates of service and diagnostic and pro-
cedure codes for the service delivered. Some datasets
also capture prescriptions. Administrative datasets
often use ICD codes. Widespread use of ICD codes
may facilitate the conduct of similar comorbidity stud-
ies in multiple jurisdictions; however, the customiza-
tion of ICD-10 in many countries threatens data
comparability.55 In many jurisdictions, administrative
claims data are population-based, accessible, and cost-
effective as compared to other data sources. However,
their validity for research must be assessed,54 and clin-
ical details are lacking. The potential applications to
comorbidity research are broad, including comorbidity
surveillance, pharmacovigilance, and evaluation of the
effect of comorbidity on health care utilization.
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Appendix e-4 describes potentially useful datasets
that include MS-relevant comorbidity and health
behavior data, worldwide. While the validity of some
of these datasets for MS research is established, fur-
ther work is necessary to validate others.
Analysis. Analytically, comorbidity can be classified as
a count of conditions, using an index, or by consider-
ing individual comorbidities. A count is the simplest
to obtain and is associated with outcomes such as
health care utilization,56 but treats all comorbidities
as equal. An index is a summary measure of comor-
bidities that may incorporate information about
severity. Weighted indices apply more importance
to some conditions than others. Some indices have
been developed for use in specific populations or for
specific outcomes (e.g., mortality); relative perfor-
mance varies across populations and outcomes.57
None has been developed for use in MS, and existing
indices may be inappropriate for MS. For example,
the Elixhauser index captures paraplegia, and other
neurologic disorders (including MS),56 potentially
confounding MS severity with comorbidity. Consid-
eration of individual comorbidities provides more
opportunity to understand interactions between co-
morbidities, but requires larger samples. Further
methodologic work is needed in this area.
RECOMMENDATIONS FOR FUTURE RESEARCH
Following presentations that reviewed the findings of
the international survey, systematic reviews, and issues
related to the measurement and analysis of comorbid-
ities, we held small group sessions to reach consensus
regarding recommendations for future research. Recog-
nizing that there would be challenges in studying all
comorbidities in the short term, the charge to the small
groups for the first and second recommendations was
to prioritize 5 comorbidities, but these recommenda-
tions are not intended to discourage work that evalu-
ates other comorbidities.
1. Establish age-specific, sex-specific, and ideally
race/ethnicity-specific incidence and prevalence
estimates for priority comorbidities in the MS
population. Based on several considerations, we
prioritized 5 comorbidities for future studies of
their incidence and prevalence in MS, including
depression, anxiety, hypertension, diabetes, and
hyperlipidemia (table e-2). First, existing literature
or clinical experience suggested they were preva-
lent in the MS population (depression, anxiety,
hypertension, hyperlipidemia). Second, little or
no information was available regarding their inci-
dence (all), or regarding age- and sex-specific
estimates of their incidence and prevalence (all).
Third, these conditions may affect the risk of MS
or differential outcomes in MS, and are potentially
treatable (all). Given the existence of some
population-based data regarding the incidence of
autoimmune disease and the low prevalence of
many autoimmune diseases in MS, these condi-
tions were given a lower priority.
2. Evaluate the effect of priority comorbidities on
MS outcomes that are relevant from the perspec-
tive of the clinician, affected individual, health
system, and society. Due to difficulties reaching
consensus regarding the top 5 comorbidities, we
prioritized 7 comorbidities for observational stud-
ies of the effect of comorbidity on MS outcomes,
including depression, anxiety, hypertension, dia-
betes, hyperlipidemia, chronic lung disease, and
autoimmune diseases. When selecting these co-
morbidities, physiologic and biological relevance
to MS, existing knowledge regarding their effects
on outcomes in MS, and their prevalence in the
MS population were considered. Given its low
prevalence, cancer was not prioritized, but was
considered highly relevant for clinical trials.4
Smoking, obesity, and physical activity were also
considered priorities for both types of studies.
However, future investigations should not be lim-
ited to these conditions. Preferred outcomes are
summarized in table e-2.
3. Include potential confounders or effect modifiers
as covariates in studies of the effect of comorbidity
on MS outcomes. Key covariates include age, sex,
race/ethnicity, socioeconomic status, and disease
duration.
4. Design observational studies that have strong
methodologic features. Given the methodologic
limitations of the existing literature, we empha-
sized the importance of sound study design. We
recognized that multiple data sources could be
used to address these questions, but the validity
of the methods used to assess comorbidity and the
outcomes of interest are critical, along with inclu-
sion of a representative study population. Specific
efforts are needed to develop an MS-specific
comorbidity index.
5. Harmonize measurement of key data elements such
as sex, race/ethnicity, clinical course, comorbidity,
and MS diagnostic criteria, and use common out-
comemeasures to facilitate pooling and comparison
of study findings. Such approaches are supported
by the National Institute of Neurological Disorders
and Stroke Common Data Elements Project.
6. Follow published guidelines when reporting study
findings.58,59 To be useful, observational studies
need to be methodologically sound and be re-
ported well. Reporting guidelines aim to improve
the quality of reporting in observational studies,
which is often poor, as is also true in the MS
comorbidity literature. The Strengthening the
Neurology 86 April 12, 2016 5
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Reporting of Observational studies in Epidemiol-
ogy statement provides guidelines for observa-
tional studies in general, while The Standards of
Reporting of Neurologic Disorders checklist pro-
vides guidelines for reporting incidence and prev-
alence studies in neurologic disease.
7. Conduct observational studies of comorbidity in
MS in all world regions. Since much of the comor-
bidity literature has arisen from few world regions
and heterogeneity in MS outcomes is well-
recognized, it is critical that investigators in areas
beyond western Europe and North America be
supported to conduct studies in their regions.
8. Explore the mechanisms of the effects of comor-
bidity on MS as a means of identifying potential
approaches to mitigating their impact. This will
require considering direct biological effects such as
accelerated neurodegeneration (as might be as-
sessed using measures of brain atrophy) or
enhanced peripheral immune activation (as might
be assessed by measuring cytokine profiles or
immune cell behavior), and indirect effects such
as diagnostic delays or differences in MS treatment
or treatment responses.
9. Conduct clinical trials of the effect of comorbidity
treatment on MS. In other diseases, there are
comorbidity-based differences in disease manage-
ment. For example, hypertension targets are lower
in diabetic patients than in patients without dia-
betes to reduce the risk of diabetes-associated
complications.60 Observational studies of the inci-
dence and prevalence of comorbidity and of the
effect of comorbidity on outcomes in MS are
needed to inform the design of these trials. Imple-
mentation research will be needed to move these
interventions into clinical practice effectively.
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